Skip to main content
SpringerLink
Log in

Lungentumoren

  • Chapter
PET/CT-Atlas

  • 3926 Accesses

Zusammenfassung

Lungenkarzinome als weltweit häufigste bösartige Tumorerkrankung teilen sich histologisch in das nichtkleinzellige und das kleinzellige Bronchialkarzinom, das bronchoalveoläre Karzinom und das neuroendokrine Karzinom. Die FDG-PET/CT wird bei Verdacht auf einen primären Lungentumor zunehmend in die bisherigen bildgebenden Modalitäten (CT, Bronchoskopie, Mediastinoskopie, MRT, Knochenszintigraphie) zur weiteren Diagnosesicherung eingebunden. Die PET/CT zeichnet sich beim T-, N- und M-Staging durch einen Informationsgewinn und damit durch eine höhere Vorhersage- bzw. Ausschlussquote aus. Lymphknotenmetastasen außerhalb des Mediastinums sowie Nebennieren-, Knochen- und Knochenmarkmetastasen spielen eine therapieentscheidende Rolle im primären Staging. Besonders in der Planung der Strahlentherapie von Lungenkarzinomen leistet die FDG-PET/CT einen essenziellen Beitrag. Nach potenziell kurativer Therapie hat sie Einfluss auf das weitere Management und die Prognosestratifikation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Antoch G, Stattaus J, Nemat AT et al. (2003) Non-small cell lung cancer: Dual modality PET/CT in preoperative staging. Radiology 229: 526–533

    Article  PubMed  Google Scholar 

  2. Bundesamt fur Strahlenschutz (2001) Teil B - IV - Strahlenexposition durch medizinische Masnahmen. http://www.bfs.de/de/bfs/publikationen/berichte/umweltradioaktivitaet/JB10TeilB_IV.pdf (Zugriff: 22.03.2015)

  3. Bundesamt fur Strahlenschutz (2012) Bekanntmachung der aktualisierten diagnostischen Referenzwerte fur nuklearmedizinische Untersuchungen. http://www.bfs.de/de/ion/medizin/diagnostik/drw_nuklearmedizin.pdf (Zugriff: 22.03.2015)

  4. Cuaron J, Dunphy M, Rimner A (2012) Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer. Front Oncol 2: 208

    Google Scholar 

  5. Czernin J (2007) PET/CT in cancer patient management. J Nucl Med: 1S–88 S

    Google Scholar 

  6. Czernin J, Auerbach MA (2005) Clinical PET/CT imaging: Promises and misconceptions. Nuklearmedizin 44 (suppl 1): S18–23

    PubMed  Google Scholar 

  7. Czernin J, Allen-Auerbach M, Schelbert HR (2007) Improvements in cancer staging with PET/CT: Literature-based evidence as of September 2006. J Nucl Med 48 (suppl 1): 78S–88 S

    CAS  PubMed  Google Scholar 

  8. Deppen SA, Blume JD, Kensinger CD et al. (2014) Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. JAMA 312(12): 1227–1236

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Deutsches Arzteblatt (2013) Malignes Pleuramesotheliom: Inzidenz, Atiologie, Diagnostik, Therapie und Arbeitsmedizin. http://www.aerzteblatt.de/archiv/137725/Malignes-Pleuramesotheliom- Inzidenz-Aetiologie-Diagnostik-Therapie-und-Arbeitsmedizin (Zugriff: 22.03.2015)

  10. Deutsche Krebsgesellschaft (2008) Kurzgefasste interdisziplinare Leitlinien 2008. Deutsche Krebsgesellschaft. http://www.krebsgesellschaft.de/wub_llkurz_2008,120883.html (Zugriff: 25.01.2010)

  11. Erasmus JJ, Page Mc Adams H, Rossi SE, Goodman PC et al. (2000) FDG PET of pleural effusions in patients with non-small cell lung cancer. Am J Roentgenol 175: 245–249

    Article  CAS  Google Scholar 

  12. Facey K, Bradbury I, Laking G, Payne E (2007) Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess Winch Engl 11(44): iii-iv, xi–267

    Google Scholar 

  13. Fleckenstein J, Hellwig D, Kremp S et al. (2011) F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial. Int J Radiat Oncol Biol Phys 81(4): e283–e289

    Article  PubMed  Google Scholar 

  14. Gemeinsamer Bundesausschuss (2007) Positronenemissionstomographie (PET). Abschlussbericht des Unterausschusses »Arztliche Behandlung« des Gemeinsamen Bundesausschusses. https://www.g-ba.de/downloads/40-268-514/2007-12-13-Abschluss- PET-NSCLC.pdf (Zugriff: 24.03.2015)

  15. Gemeinsamer Bundesausschuss (2008) Positronenemissionstomographie SCLC. Zusammenfassende Dokumentation. https://www.g-ba.de/downloads/40-268-682/2008-05-26-Abschluss- PET-SCLC.pdf (Zugriff: 24.03.2015)

  16. Gerbaudo VH, Sugarbaker DJ, Britz-Cunningham S et al. (2002) Assessment of malignant pleural mesothelioma with 18F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology. J Nucl Med 43: 1144–1149

    PubMed  Google Scholar 

  17. Goeckenjan G, Sitter H, Thomas M et al. (2011) Pravention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Pneumologie 2011: 65: 51–75

    Article  Google Scholar 

  18. Hany TF, Steinert HC, Goerres GW, Buck A, von Schulthess GK (2002) PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology 225(2): 575–581

    Article  PubMed  Google Scholar 

  19. Hellwig D, Baum RP, Kirsch C (2009) FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nukl Nucl Med 48(2): 59–69, quiz N8–N9

    Google Scholar 

  20. Huang W, Liu B, Fan M et al. (2015) The early predictive value of a decrease of metabolic tumor volume in repeated (18)F-FDG PET/CT for recurrence of locally advanced non-small cell lung cancer with concurrent radiochemotherapy. Eur J Radiol 84(3): 482–488. doi:10.1016/j.ejrad.2014.11.020

    Article  PubMed  Google Scholar 

  21. Im H-J, Pak K, Cheon GJ et al. (2015) Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging 42(2): 241–251

    Article  CAS  PubMed  Google Scholar 

  22. Ji C, Zhang B, Zhu W et al. (2014) Evaluation of (18)F-fluorodeoxyglucose uptake in enlarged mediastinal lymph nodes in patients with lung cancer. Int J Clin Exp Pathol 7(11): 8227–8234

    PubMed  PubMed Central  Google Scholar 

  23. Kim M-H, Lee JS, Mok JH et al. (2014) Metabolic burden measured by (18)f-fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in patients with small cell lung cancer. Cancer Res Treat Off J Korean Cancer Assoc 46(2): 165–171

    Google Scholar 

  24. Klabatsa A, Chicklore S, Barrington SF, Goh V, Lang-Lazdunski L, Cook GJR (2014) The association of 18F-FDG PET/CT parameters with survival in malignant pleural mesothelioma. Eur J Nucl Med Mol Imaging 41(2): 276–282

    Article  CAS  PubMed  Google Scholar 

  25. Klett R, Rohrl A, Bauer R (2000) Nachtliche und belastungsbedingte pektanginose Beschwerden durch vertebragene Dysfunktion. Herz/Kreislauf 32: 309–311

    Google Scholar 

  26. Krause BJ, Schwarzenbock S, Souvatzoglou M (2013) FDG PET and PET/CT. Recent Results Cancer Res Fortschritte Krebsforsch Prog Dans Rech Sur Cancer 187: 351–369. doi:10.1007/978-3-642- 10853-2_12

    CAS  Google Scholar 

  27. Kruger S, Buck AK, Mottaghy FM et al. (2009) Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging 36(11): 1807–1812

    Article  PubMed  Google Scholar 

  28. Kung BT, Auyong TK, Tong CM (2014) Prevalence of Detecting Unknown Cerebral Metastases in Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and its Potential Clinical Impact. World J Nucl Med 13(2): 108–111. doi:10.4103/1450-1147.139141

    Google Scholar 

  29. Lardinois D, Weder W, Hany TF et al. (2003) Staging of non-small cell lung cancer with integrated positron emission tomography and computed tomography. N Engl J Med 348: 2500–2507

    Article  PubMed  Google Scholar 

  30. Larson SM, Erdi Y, Akhurst T et al. (1999) Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging Off J Inst Clin PET 2(3): 159–171

    Article  Google Scholar 

  31. Li J, Xu W, Kong F, Sun X, Zuo X (2013) Meta-analysis: accuracy of 18FDG PET-CT for distant metastasis staging in lung cancer patients. Surg Oncol 22(3): 151–155

    Article  PubMed  Google Scholar 

  32. Liu S, Cheng H, Yao S et al. (2010) The clinical application value of PET/CT in adenocarcinoma with bronchioloalveolar carcinoma features. Ann Nucl Med 24(7): 541–547

    Article  PubMed  Google Scholar 

  33. Lv Y-L, Yuan D-M, Wang K et al. (2011) Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer 6(8):1350–1358

    Google Scholar 

  34. Mac Manus MP, Hicks RJ (2012) The role of positron emission tomography/computed tomography in radiation therapy planning for patients with lung cancer. Semin Nucl Med 42(5): 308–319

    Article  PubMed  Google Scholar 

  35. Marcus C, Paidpally V, Antoniou A, Zaheer A, Wahl RL, Subramaniam RM (2015). 18F-FDG PET/CT and Lung Cancer: Value of Fourth and Subsequent Posttherapy Follow-up Scans for Patient Management. J Nucl Med Off Publ Soc Nucl Med 56(2): 204–208. doi:10.2967/jnumed.114.147884

    Google Scholar 

  36. Minamimoto R, Senda M, Jinnouchi S et al. (2014) Detection of lung cancer by FDG-PET cancer screening program: a nationwide Japanese survey. Anticancer Res 34(1): 183–189

    PubMed  Google Scholar 

  37. Nguyen P, Bhatt M, Bashirzadeh F et al. (2015) Comparison of objective criteria and expert visual interpretation to classify benign and malignant hilar and mediastinal nodes on 18-F FDG PET/CT. Respirol Carlton Vic 20(1): 129–137. doi:10.1111/resp.12409

    Article  Google Scholar 

  38. Ordu C, Selcuk NA, Erdogan E et al. (2014) Does early PET/CT assesment of response to chemotherapy predicts survival in patients with advanced stage non-small-cell lung cancer? Medicine 93(28): e299. doi:10.1097/MD.0000000000000299

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. van Overhage H, Broekel K, Heijenbrok MW et al. (2004) Metastases in supraclavicular lymphnodes in lung cancer: Assessment with palpation, US and CT. Radiology 232: 75–80

    Article  Google Scholar 

  40. Qu X, Huang X, Yan W, Wu L, Dai K (2012) A meta-analysis of 18FDG-PET-CT, 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol 81(5): 1007–1015

    Article  PubMed  Google Scholar 

  41. Pitts A, Ih G, Wei M et al. (2013) Clinical utility of FDG-PET for diagnosis of adrenal mass: a large single-center experience. Horm Athens Greece 12(3): 417–427

    Google Scholar 

  42. Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (2013) Krebs in Deutschland 2009/2010. Beitrage zur Gesundheitsberichterstattung des Bundes. 9. Ausg. Berlin, S 60–63. http://www.rki.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2013/krebs_in_ deutschland_2013.pdf;jsessionid = 8D65E3DB2765A1D4C6CE- 39F27AB011D8.2_cid372?__blob = publicationFile (Zugriff: 18.03.2015)

  43. Sawada E, Nambu A, Motosugi U et al. (2010) Localized mucinous bronchioloalveolar carcinoma of the lung: thin-section computed tomography and fluorodeoxyglucose positron emission tomography findings. Jpn J Radiol 28(4): 251–258

    Google Scholar 

  44. Schaffler GJ, Wolf G, Schoellnast H et al. (2004) Non-small cell lung cancer: Evaluation of pleural abnormalities on CT scans with 18F FDG PET. Radiology 231: 858–865

    Article  PubMed  Google Scholar 

  45. Schmidt-Hansen M, Baldwin DR, Hasler E, Zamora J, Abraira V, Roque I Figuls M (2014) PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable nonsmall cell lung cancer. Cochrane Database Syst Rev 11:CD009519

    Google Scholar 

  46. Shimizu K, Maeda A, Yukawa T et al. (2014) Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose- positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma. World J Surg Oncol 12: 343

    Article  PubMed  PubMed Central  Google Scholar 

  47. Shreve P, Faasse T (2013) Role of positron emission tomographycomputed tomography in pulmonary neoplasms. Radiol Clin North Am 51(5): 767–779

    Article  PubMed  Google Scholar 

  48. Sim YT, Goh YG, Dempsey MF, Han S, Poon FW (2013) PET-CT evaluation of solitary pulmonary nodules: correlation with maximum standardized uptake value and pathology. Lung 191(6): 625–632. doi:10.1007/s00408-013-9500-6

    Article  PubMed  Google Scholar 

  49. Skoura EV, Exarhos D, Skilakaki M et al. (2009) Contribution of 18F-PET/CT in the management of patients with bronchioalveolar carcinoma (BAC): work in progress. Eur J Nucl Med Mol Imaging, Abstracts Ann Congr EANM 2009: P118, S333

    Google Scholar 

  50. Terada T, Tabata C, Tabata R et al. (2012) Clinical utility of 18-fluorodeoxyglucose positron emission tomography/computed tomography in malignant pleural mesothelioma. Exp Ther Med 4(2): 197–200

    PubMed  PubMed Central  Google Scholar 

  51. van Tinteren H, Hoekstra OS, Smit EF et al. (2002) Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non small cell lung cancer: The PLUS multicentre randomized trial. Lancet 359: 1388–1392

    Article  PubMed  Google Scholar 

  52. Toba H, Kondo K, Otsuka H et al. (2010) Diagnosis of the presence of lymph node metastasis and decision of operative indication using fluorodeoxyglucose-positron emission tomography and computed tomography in patients with primary lung cancer. J Med Investig JMI 57(3–4): 305–313

    Article  Google Scholar 

  53. Van Baardwijk A, Reymen B, Wanders S et al. (2012) Mature results of a phase II trial on individualised accelerated radiotherapy based on normal tissue constraints in concurrent chemo-radiation for stage III non-small cell lung cancer. Eur J Cancer Oxf Engl 48 (15): 2339–2346

    Article  Google Scholar 

  54. Van Gool MH, Aukema TS, Hartemink KJ, Valdes Olmos RA, van Tinteren H, Klomp HM (2014) FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC. World J Radiol 6(7): 392–398

    Article  PubMed  PubMed Central  Google Scholar 

  55. Verboom P, van Tinteren H, Hoekstra OS et al. (2003) Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 30(11): 1444–1449. doi:10.1007/s00259-003-1199-9

    Article  PubMed  Google Scholar 

  56. Wahl RL (2004) Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med (suppl 1) 45: 82S–95 S

    Google Scholar 

  57. Wever WD, Stroobants S, Coolen J, Verschakelen JA (2009) Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration. Eur Respir J 33(1): 201–212

    Article  PubMed  Google Scholar 

  58. Yu J, Li X, Xing L et al. (2009) Comparison of tumor volumes as determined by pathologic examination and FDG-PET/CT images of non-small-cell lung cancer: a pilot study. Int J Radiat Oncol Biol Phys 75(5): 1468–1474

    Article  PubMed  Google Scholar 

  59. Zahid I, Sharif S, Routledge T, Scarci M (2011) What is the best way to diagnose and stage malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg 12(2): 254–259

    Article  PubMed  Google Scholar 

  60. Zhang H, Wroblewski K, Liao S et al. (2013) Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer. Acad Radiol 20(1): 32–40

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diagnostisch Therapeutisches Zentrum, Kadiner Straße 23, 10243, Berlin

    Prof. Dr. med. Wolfgang Mohnike

  2. Kuckucksweg 25, 61462, Königstein/Taunus

    Prof. Dr. med. Gustav Hör

  3. Klinik für Diagnostische und Therapeutische, Nuklearmedizin, Klinikum Fulda gAG, Pacelliallee 4, 36043, Fulda

    Dr. med. Andreas Hertel

Authors
  1. Prof. Dr. med. Wolfgang Mohnike
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. Gustav Hör
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dr. med. Andreas Hertel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Diagnostisch Therapeutisches Zentrum, Berlin, Deutschland

    Wolfgang Mohnike

  2. Königstein, Deutschland

    Gustav Hör

  3. Klinikum für Nuklearmedizin, Klinikum Fulda, Fulda, Deutschland

    Andreas Hertel

  4. UCLA Molecular & Medical Pharmacology, Los Angeles, CA, USA

    Heinrich Schelbert

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Mohnike, W., Hör, G., Hertel, A. (2016). Lungentumoren. In: Mohnike, W., Hör, G., Hertel, A., Schelbert, H. (eds) PET/CT-Atlas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-48842-3_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-48842-3_6

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-48841-6

  • Online ISBN: 978-3-662-48842-3

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation